d-Cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window

European Journal of Pharmacology

Volumn 629, Issue 1-3, 2010, Pages 25-30

  Adeleye, Amos ^a,b   Shohami, Esther ^a   Nachman, Dean ^a,b   Alexandrovich, Alexander ^a   Trembovler, Victoria ^a   Yaka, Rami ^a   Shoshan, Yigal ^b   Dhawan, Jasbeer ^c   Biegon, Anat ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Glutamate; Head injury; N methyl d aspartate (NMDA) receptor; Neuroprotection

Indexed keywords

CYCLOSERINE; DIZOCILPINE; DRUG VEHICLE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; COGNITION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INDICATION; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SCORING SYSTEM; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN INJURIES; CYCLOSERINE; DIZOCILPINE MALEATE; DRUG ADMINISTRATION SCHEDULE; MALE; MICE; RECEPTORS, N-METHYL-D-ASPARTATE; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 74149085435     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.11.066     Document Type: Article

References (52)

1. Alessandri B., Landolt H., Langemann H., Gregorin J., Hall J., and Gratzl O. Application of glutamate in the cortex of rats: a microdialysis study. Acta Neurochir. Suppl. 67 (1996) 6-12
2. Andersen J.M., Lindberg V., and Myhrer T. Effects of scopolamine and d-cycloserine on non-spatial reference memory in rats. Behav. Brain Res. 129 (2002) 211-216
3. Baker A.J., Moulton R.J., MacMillan V.H., and Shedden P.M. Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans. J. Neurosurg. 79 (1993) 369-372
4. Barth T.M., Grant M.L., and Schallert T. Effect of MK801 on recovery from sensorimotor cortex lesion. Stroke 11 (1990) 153-157
5. Beauchamp K., Mutlak H., Smith W.R., Shohami E., and Stahel P.F. Pharmacology of traumatic brain injury - where is the "golden bullet"?. Mol. Med. 14 (2008) 731-740
6. Belayev L., Obenaus A., Zhao W., Saul I., Busto R., Wu C., Vigdorchik A., Lin B., and Ginsberg M.D. Experimental intracerebral hematoma in the rat: characterization by sequential magnetic resonance imaging, behavior, and histopathology. Effect of albumin therapy. Brain Res. 1157 (2007) 146-155
7. Beni-Adani L., Gozes I., Cohen Y., Assaf Y., Steindart R., Brenneman D.E., Eizenberg O., Trembovler V., and Shohami E. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J. Pharmacol. Exp. Ther. 296 (2001) 57-63
8. Biegon A., Alvarado M., Budinger T.F., Grossman R., Hensley K., West M.S., Kotake Y., Ono M., and Floyd R.A. Region selective effects of neuroinflammation and antioxidant treatment on peripheral benzodiazepine receptors and NMDA receptors in the rat brain. J. Neurochem. 82 (2002) 1-11
9. Biegon A., Fry P.A., Paden C.M., Alexandrovich A., Tsenter J., and Shohami E. Dynamic changes in N-methyl-d-aspartate receptors after closed head injury in mice: Implications for treatment of neurological and cognitive deficits. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 5117-5122
10. Brown J.I., Baker A.J., Konasiewicz S.J., and Moulton R.J. Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans. J. Neurotrauma 15 (1998) 253-263
11. Bullock R., Zauner A., Woodward J.J., et al. Factors affecting excitatory amino acid release following severe human head injury. J. Neurosurg. 89 (1998) 507-518
12. Chen M., Bullock R., Graham D.I., Frey P., Lowe D., and McCulloch J. Evaluation of a competitive NMDA antagonist (D-CPPene) in feline focal cerebral ischemia. Ann. Neurol. 30 (1991) 62-70
13. Danysz W., and Parsons C.G. Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 50 (1998) 597-664
14. Di X., and Bullock R. Effect of the novel high-affinity glycine-site N-methyl-d-aspartate antagonist ACEA-1021 on 125I-MK-801 binding after subdural hematoma in the rat: an in vivo autoradiographic study. J. Neurosurg. 85 (1996) 655-661
15. Duncan E.J., Szilagyi S., Schwartz M.P., Bugarski-Kirola D., Kunzova A., Negi S., Stephanides M., Efferen T.R., Angrist B., Peselow E., Corwin J., Gonzenbach S., and Rotrosen J.P. Effects of d-cycloserine on negative symptoms in schizophrenia. Schizophr. Res. 71 (2004) 239-248
16. Emmett M.R., Mick S.J., Cler J.A., Rao T.S., Iyengar S., and Wood P.L. Actions of d-cycloserine at the N-methyl-d-aspartate-associated glycine receptor site in vivo. Neuropharmacology 30 (1991) 1167-1671
17. Faden A.I., Demediuk P., Panter S.S., and Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 244 (1989) 798-800
18. Fisher M. The travails of neuroprotective drug development for acute ischemic stroke. Eur. Neurol. 40 (1998) 65-66
19. Friedman L.K., Ginsberg M.D., Belayev L., Busto R., Alonso O.F., Lin B., and Globus M.Y. Intraischemic but not postischemic hypothermia prevents non-selective hippocampal downregulation of AMPA and NMDA receptor gene expression after global ischemia. Brain Res. Mol. Brain Res. 86 (2001) 34-47
20. Grossman R., Shohami E., Alexandrovich A., Yatsiv I., Kloog A., and Biegon A. Increase in peripheral benzodiazepine receptors and loss of glutamate NMDA receptors in a mouse model of closed head injury: a quantitative autoradiographic study. NeuroImage 20 (2003) 1971-1981
21. Hayes R.L., Jenkins L.W., Lyeth B.G., Balster R.L., Robinson S.E., Clifton G.L., Stubbins J.F., and Young H.F. Pretreatment with phencyclidine, an N-methyl-d-aspartate antagonist, attenuates long-term behavioral deficits in the rat produced by traumatic brain injury. J. Neurotrauma 5 (1988) 259-274
22. Heifets L.B. Antimycobacterial drugs. Semin. Respir. Infect. 9 (1994) 84-103
23. Heresco-Levy U., Kremer I., Javitt D.C., Goichman R., Reshef A., Blanaru M., and Cohen T. Pilot-controlled trial of d-cycloserine for the treatment of post-traumatic stress disorder. Int. J. Neuropsychopharmacol. 5 (2002) 301-307
24. Hoane M.R., Barbay S., and Barth T.M. Large cortical lesions produce enduring forelimb placing deficits in untreated rats and treatment with NMDA antagonists or antioxidant drugs induces behavioral recovery. Brain Res. Bull. 53 (2000) 175-186
25. Ji S., Kronenberg G., Balkaya M., Furber K., Gertz K., Kettenmann H., and Endres M. Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome. Exp. Neurol. 216 (2009) 321-328
26. Kalia L.V., Kalia S.K., and Salter M.W. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 7 (2008) 742-755
27. Kokiko O.N., Murashov A.K., and Hoane M.R. Administration of raloxifene reduces sensorimotor and working memory deficits following traumatic brain injury. Behav. Brain Res. 170 (2006) 233-240
28. Koskinen S., and Alaranta H. Traumatic brain injury in Finland 1991-2005: a nationwide register study of hospitalized and fatal TBI. Brain Inj. 22 (2008) 205-214
29. Kroppenstedt S.N., Schneider G.H., Thomale U.W., and Unterberg A.W. Protective effects of aptiganel HCl (Cerestat) following controlled cortical impact injury in the rat. J. Neurotrauma 15 (1998) 191-197
30. Laake, K., Oeksengaard, A. R. 2002. d-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev, CD003153.
31. Lees K.R. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 49 (1997) S66-S69
32. Lynch D.R., and Dawson T.M. Secondary mechanisms in neuronal trauma. Curr. Opin. Neurol. 7 (1994) 510-516
33. Maas A.I., Steyerberg E.W., Murray G.D., Bullock R., Baethmann A., Marshall L.F., and Teasdale G.M. Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations. Neurosurgery 44 (1999) 1286-1298
34. Malenka R.C., and Nicoll R.A. Long-term potentiation-a decade of progress?. Science 285 (1999) 1870-1874
35. Mark V.W., Taub E., Perkins C., Gauthier L., and Uswatte G. MRI infarction load and CI therapy outcomes for chronic post-stroke hemiparesis. Restor. Neurol. Neurosci. 26 (2008) 13-33
36. Miller L.P., Lyeth B.G., Jenkins L.W., Oleniak L., Panchision D., Hamm R.J., Phillips L.L., Dixon C.E., Clifton G.L., and Hayes R.L. Excitatory amino acid receptor subtype binding following traumatic brain injury. Brain Res. 526 (1991) 103-107
37. Myburgh J.A., Cooper D.J., Finfer S.R., et al. Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New Zealand. J. Trauma 64 (2008) 854-862
38. Narayan R.K., Michel M.E., Ansell B., Baethmann A., Biegon A., Bracken M.B., et al. Clinical trials in head injury. J. Neurotrauma 19 (2002) 503-557
39. Nitsche M.A., Jaussi W., Liebetanz D., Lang N., Tergau F., and Paulus W. Consolidation of human motor cortical neuroplasticity by d-cycloserine. Neuropsychopharmacology 29 (2004) 1573-1578
40. Palmer A.M., Marion D.W., Botscheller M.L., Swedlow P.E., Styren S.D., and DeKosky S.T. Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model. J. Neurochem. 61 (1993) 2015-2024
41. Panter S.S., and Faden A.I. Pretreatment with NMDA antagonists limits release of excitatory amino acids following traumatic brain injury. Neurosci. Lett. 136 (1992) 165-168
42. Rod M.R., and Auer R.N. Pre- and post-ischemic administration of dizocilpine (MK-801) reduces cerebral necrosis in the rat. Can. J. Neurol. Sci. 16 (1989) 340-344
43. Schneider J.S., Tinker J.P., Van Velson M., and Giardiniere M. Effects of the partial glycine agonist d-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. Brain Res. 860 (2000) 190-194
44. Schumann J., Alexandrovich A.G., Biegon A., and Yaka R. Inhibition of NR2B phosphorylation restores alterations in NMDA receptor expression and improves functional recovery following traumatic brain injury in mice. J. Neurotrauma 25 (2008) 945-957
45. Shapira Y., Yadid G., Cotev S., Niska A., and Shohami E. Protective effect of MK-801 in experimental brain injury. J. Neurotrauma 7 (1990) 131-139
46. Sihver S., Marklund N., Hillered L., Langstrom B., Watanabe Y., and Bergstrom M. Changes in mACh, NMDA and GABA(A) receptor binding after lateral fluid-percussion injury: in vitro autoradiography of rat brain frozen sections. J. Neurochem. 78 (2001) 417-423
47. Temple M.D., and Hamm R.J. Chronic, post-injury administration of d-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury. Brain Res. 741 (1996) 246-251
48. Thurman D.J., Alverson C., Dunn K.A., Guerrero J., and Sniezek J.E. Traumatic brain injury in the United States: a public health perspective. J. Head Trauma Rehabil. 14 (1999) 602-615
49. Tolias C.M., and Bullock M.R. Critical appraisal of neuroprotection trials in head injury: what have we learned?. NeuroRx 1 (2004) 71-79
50. Tsenter J., Beni-Adani L., Assaf Y., Alexandrovich A.G., Trembovler V., and Shohami E. Dynamic changes in the recovery after traumatic brain injury in mice: effect of injury severity on T2-weighted MRI abnormalities, motor and cognitive function. J. Neurotrauma 25 (2008) 324-333
51. Wolosker H. NMDA receptor regulation by d-serine: new findings and perspectives. Mol. Neurobiol. 36 (2007) 152-164
52. Yaka R., Biegon A., Grigoriadis N., Simeonidou C., Grigoriadis S., Alexandrovich A.G., Matzner H., Schumann J., Trembolver V., Tsenter J., and Shohami E. d-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J. 21 (2007) 2033-2041